October 16, 2019

Aprecia the 3dp pharmaceutical company is attending CPhI Worldwide

attend Dr. Jae Yoo's discussion of 3D-Printing and the personalization of medicines

3D-Printing pharma industry expert, Dr. Jae D. Yoo, PhD., MBA, Senior Vice President & Chief Technology Officer at Aprecia Pharmaceuticals will present a case study in the panel discussion entitled:

Made to Order: 3D-Printing for Personalized Medicines

Nov.  7, 2019 - 10:30 - 11:40 at ICSE Theatre 120D40

As the Pharma industry shifts from volume to value - addressing smaller patient populations and orphan diseases, 3D printing technologies have a transformational role to play. With the promise of increasingly personalized and sophisticated solutions which offer significant benefits in terms of formulation, solubility and controlled release, what does the future hold?

Discussion will include: 

Current capabilities and the future potential
Impact for personalized medicines
An overview of technologies on the market
Case Study - Aprecia Pharmaceuticals

Meet with Aprecia executives at CPhI Worldwide 2019

Frankfurt, Germany, November 5 - 7, 2019

Meet with Aprecia Executives to discuss how 3D-Printing can create new opportunities for improved therapeutics, entirely new dosage forms and lifecycle management.

Key Topics for Discussion include:

Product Collaboration
CDMO Partnership
Licensing

Contact Kirk Donaldson, VP Business Development & Alliance Management to schedule a meeting in Frankfurt. Kirk.Donaldson@Aprecia.com

About Aprecia pharmaceuticals

Founded in 2003, Aprecia Pharmaceuticals received the first and only FDA-approval for a three-dimensionally-printed (3DP) pharmaceutical product in 2015. Aprecia uses its ZipDose® Technology to create rapidly disintegrating oral dosage forms that are easy to take and easy to administer. Without compression during the 3DP manufacturing process, engineered and coated particles for taste masking or modified release can be incorporated into large dose products. Additionally, with the ease of swallowing enabled by 3D-printed tablets even at large doses, some patients may experience a reduction in pill burden by achieving their prescribed dose with fewer tablets. Aprecia directly owns a patent estate for novel 3DP machines and pharmaceutical 3DP applications and licenses its exclusive technology platform to pharmaceutical partners as a means to extend product lines, improve patient reach and experience, and address FDA requirements as a pediatric delivery form.

Contact Kirk Donaldson, VP Business Development & Alliance Management to schedule a meeting in Frankfurt. Kirk.Donaldson@Aprecia.com